Johnson & Johnson reports late breaking clinical science data, presented at the European Society of Cardiology Congress and simultaneously published in the New England Journal of Medicine, finds at up to 10 years, when compared to standard care, routine use of Impella CP in patients who have had a heart attack with cardiogenic shock leads to an absolute mortality reduction of 16.3%. When compared to the control arm at 10 years, Impella CP patients gained an average of 600 additional days alive, the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Apple, Super Micro, Walmart, Exxon, J&J: Insider Sales Shock
- JNJ halts development of nipocalimab in combination with anti-TNFalpha therapy
- AbbVie Bets $1.2 Billion on Psychedelic Depression Drug to Boost Mental Health Pipeline
- Boeing, Johnson & Johnson, Uber, Costco, Energy Transfer: Insider Moves Unveiled!
- Trump Weekly: Trump adds goods subject to steel, aluminum tariffs